Hepatitis B reactivation is a clinical risk mechanism in which chronic or resolved (past) infection — sustained by the virus's capacity to persist latently as covalently closed circular DNA integrated in the host genome — can reactivate under immunosuppressive anti-cancer therapy, with reactivation risk stratified by serologic infection status (chronic vs. past, determined via a three-test panel: surface antigen, core antibody, and surface antibody) and by the degree of immunosuppression conferred by a given therapy class (e.g., anti-CD20 antibodies and stem-cell transplant conferring high risk; checkpoint inhibitors and corticosteroids conferring intermediate/adjunct risk). This belongs to hematology-oncology and hepatology, specifically infection-risk management in immunosuppressive cancer therapy, and relates to the broader disciplines of virology (latent viral persistence) and clinical epidemiology (risk-stratified screening policy).
Hepatitis B reactivation is a clinical risk mechanism in which chronic or resolved (past) infection — sustained by the virus's capacity to persist latently as covalently closed circular DNA integrate…